ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Insmed Initiates ARIKAYCE Trial for MAC Lung Disease americanpharmaceuticalreview
January 11, 2021Insmed announced the first patient was dosed in the frontline clinical trial program of ARIKAYCE? (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Pharma Sources Insight January 2025
